Patent · US Active

Monoclonal antibody inhibitor of Factor XIIa

US12415866B2 · kind B2 · utility

0Cited by

6References

13Claims

0Family size

Assignee

Takeda Pharmaceutical Company Limited · JP

Inventors

Shauna Mason · Arlington, US
Jon A. Kenniston · Hingham, US
Andrew Nixon · Hanover, US
Daniel J. Sexton · Melrose, US
Stephen R. Comeau · Avon, US
Burt Adelman · Concord, US

Key dates

Filing date	Dec 29, 2020
Grant date	Sep 16, 2025
Priority date	—
Expiry date	Jun 18, 2044

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.